<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099641</url>
  </required_header>
  <id_info>
    <org_study_id>ONCG100</org_study_id>
    <secondary_id>2019-000949-13</secondary_id>
    <secondary_id>KEYNOTE PN978</secondary_id>
    <nct_id>NCT04099641</nct_id>
  </id_info>
  <brief_title>An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients</brief_title>
  <official_title>A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncXerna Theraputics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OncXerna Theraputics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the combination of bavituximab and pembrolizumab in the treatment of&#xD;
      gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that&#xD;
      is not yet approved by the FDA, and pembrolizumab known as Keytruda.&#xD;
&#xD;
      There is no expanded access program available for the investigational agents per this&#xD;
      protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of Treatment Emergent Adverse Events(TEAE)</measure>
    <time_frame>From first dose through 30 days after last dose</time_frame>
    <description>Incidence by severity of TEAEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, including changes in clinical laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>Objective response rate (ORR) as assessed by the Investigator per RECIST version1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>GastroEsophageal Cancer</condition>
  <arm_group>
    <arm_group_label>bavituximab and pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bavituximab 3mg/kg IV weekly in combination with pembrolizumab 200mg IV given once every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bavituximab</intervention_name>
    <description>Bavituximab IV infusion</description>
    <arm_group_label>bavituximab and pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Injection</intervention_name>
    <description>Pembrolizumab IV Infusion</description>
    <arm_group_label>bavituximab and pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Men and women ≥ 18 years old; ≥ 20 years old in South Korea and Taiwan&#xD;
&#xD;
          -  Unresectable metastatic or locally advanced gastric or GEJ adenocarcinoma&#xD;
&#xD;
          -  Progressed on and/or after at least 1 prior regimen for metastatic disease or achieved&#xD;
             stable disease or better in two consecutive scans to PD-1/PD-L1 inhibition alone or in&#xD;
             combination with chemotherapy and relapsed&#xD;
&#xD;
          -  Willing and able to provide fresh formalin-fixed paraffin-embedded tissue tumor sample&#xD;
&#xD;
          -  Presence of at least one measurable lesion&#xD;
&#xD;
          -  ECOG of 0 or 1&#xD;
&#xD;
          -  Has adequate organ functions&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 72 hours prior to start of study treatment.&#xD;
&#xD;
          -  Women must not be breastfeeding.&#xD;
&#xD;
          -  Women of childbearing potential , must agree to follow instructions for highly&#xD;
             effective method(s) of contraception&#xD;
&#xD;
          -  Males who are sexually active with women of childbearing potential must agree to&#xD;
             follow instructions for highly effective method(s) of contraception&#xD;
&#xD;
          -  Has adequate treatment washout period before start of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received any form of anti-phosphatidylserine therapies&#xD;
&#xD;
          -  Prior treatment with any checkpoint inhibitor or other therapies targeting T-cell&#xD;
             control&#xD;
&#xD;
          -  Known microsatellite instability-high (MSI-H) gastric or GEJ adenocarcinoma&#xD;
&#xD;
          -  Medical history of myocardial infarction within 6 months before registration,&#xD;
             symptomatic congestive heart failure (CHF) , troponin levels consistent with&#xD;
             myocardial infarction, unstable angina, or serious cardiac arrhythmia&#xD;
&#xD;
          -  Weight loss &gt;10% over 2 months prior to first dose of study treatment&#xD;
&#xD;
          -  History of pneumonitis that required steroids or has current pneumonitis&#xD;
&#xD;
          -  Has known active CNS metastases/and or carcinomatous meningitis&#xD;
&#xD;
          -  Known additional malignancy that is progressing or has required active treatment in&#xD;
             within the past 3 years&#xD;
&#xD;
          -  An active infection requiring systemic therapy&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection or known acute hepatitis B or C&#xD;
             infection&#xD;
&#xD;
          -  Unresolved toxicities from previous cancer treatments&#xD;
&#xD;
          -  History or current evidence of any condition, therapy, or laboratory abnormality that&#xD;
             might confound the results of the study, interfere with the participant's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the participant to participate, in the opinion of the treating investigator&#xD;
&#xD;
          -  Active autoimmune disease or history of chronic recurrent autoimmune disease&#xD;
&#xD;
          -  Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.&#xD;
&#xD;
          -  History of infusion reactions to any component/excipient of bavituximab&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to mAbs.&#xD;
&#xD;
          -  Systemic steroid therapy within 7 days prior to the first dose of study treatment&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to first dose of study drug.&#xD;
&#xD;
          -  Prior organ transplantation including allogeneic or autologous stem-cell&#xD;
             transplantation&#xD;
&#xD;
          -  Currently participating in or has participated in a study of an investigational agent&#xD;
             or has used an investigational device within 4 weeks prior to the first dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Receipt of treatment with immunotherapy, biological therapies, or therapeutic doses of&#xD;
             hormonal therapies within 3 weeks of scheduled C1D1 dosing&#xD;
&#xD;
          -  Known psychiatric, substance abuse disorder, or geographical travel limitations that&#xD;
             would interfere with participant's ability to cooperate with the requirements of the&#xD;
             study&#xD;
&#xD;
          -  Pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida - Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - Washington University Medical Campus</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White Plains Hospital - Center for Cancer Care</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Health Office of Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America at Eastern Regional Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sara Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>702-210</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation - Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Bavituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

